PMID- 28841363
OWN - NLM
STAT- MEDLINE
DCOM- 20180514
LR  - 20231104
IS  - 2164-554X (Electronic)
IS  - 2164-5515 (Print)
IS  - 2164-5515 (Linking)
VI  - 13
IP  - 9
DP  - 2017 Sep 2
TI  - Tocilizumab (Actemra).
PG  - 1972-1988
LID - 10.1080/21645515.2017.1316909 [doi]
AB  - Tocilizumab (TCZ), is a recombinant humanized anti-interleukin-6 receptor (IL-6R) 
      monoclonal antibody which has a main use in the treatment of rheumatoid 
      arthritis, systemic juvenile idiopathic arthritis (sJIA) and polyarticular 
      juvenile idiopathic arthritis (pJIA). This article provides an overview of TCZ 
      including looking into the past at the discovery of interleukin-6 (IL-6) as a 
      pro-inflammatory cytokine. It also looks at how tocilizumab was developed, 
      manufactured and tested to ensure both safety and efficacy in a human population. 
      The article then explores the advantages and disadvantages of using TCZ when 
      compared to other biologics approved in RA, sJIA and pJIA and finally looks ahead 
      to the future and the emerging role of IL-6 and its blockade by TCZ as a 
      treatment for giant cell arteritis (GCA), polymyalgia rheumatica (PMR) and large 
      vessel vasculitis (LVV).
FAU - Sheppard, Martin
AU  - Sheppard M
AD  - a Southend University Hospital NHS Foundation Trust , Westcliff on Sea , UK.
FAU - Laskou, Faidra
AU  - Laskou F
AD  - a Southend University Hospital NHS Foundation Trust , Westcliff on Sea , UK.
FAU - Stapleton, Philip P
AU  - Stapleton PP
AD  - a Southend University Hospital NHS Foundation Trust , Westcliff on Sea , UK.
FAU - Hadavi, Shahryar
AU  - Hadavi S
AD  - a Southend University Hospital NHS Foundation Trust , Westcliff on Sea , UK.
FAU - Dasgupta, Bhaskar
AU  - Dasgupta B
AD  - a Southend University Hospital NHS Foundation Trust , Westcliff on Sea , UK.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Hum Vaccin Immunother
JT  - Human vaccines & immunotherapeutics
JID - 101572652
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (IL6 protein, human)
RN  - 0 (Interleukin-6)
RN  - 0 (Receptors, Interleukin-6)
RN  - I031V2H011 (tocilizumab)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal, Humanized/adverse effects/pharmacokinetics/*therapeutic 
      use
MH  - Arthritis, Rheumatoid/*drug therapy/immunology
MH  - Drug Approval
MH  - Humans
MH  - Interleukin-6/immunology
MH  - Polymyalgia Rheumatica/drug therapy
MH  - Receptors, Interleukin-6/*antagonists & inhibitors/*immunology
MH  - Vasculitis/drug therapy
PMC - PMC5612212
OTO - NOTNLM
OT  - giant cell arteritis
OT  - interleukin-6
OT  - monoclonal antibody
OT  - rheumatoid arthritis
OT  - tocilizumab
OT  - vasculitis
EDAT- 2017/08/26 06:00
MHDA- 2018/05/15 06:00
PMCR- 2018/08/25
CRDT- 2017/08/26 06:00
PHST- 2017/08/26 06:00 [pubmed]
PHST- 2018/05/15 06:00 [medline]
PHST- 2017/08/26 06:00 [entrez]
PHST- 2018/08/25 00:00 [pmc-release]
AID - 1316909 [pii]
AID - 10.1080/21645515.2017.1316909 [doi]
PST - ppublish
SO  - Hum Vaccin Immunother. 2017 Sep 2;13(9):1972-1988. doi: 
      10.1080/21645515.2017.1316909.